

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF :
Hepworth, David, et al

APPLICATION NO.: 10/800,065 : Examiner: Janet L. Coppins

FILING DATE: March 12, 2004 : Group Art Unit: 1626

TITLE: 3-(1-[3-(1,3-Benzothiazol-6-yl)
propylcarbamoyl]cycloalkyl)propanoic Acid
Derivatives as NEP Inhibitors

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**PETITION FOR REVIVAL OF
UNINTENTIONALLY ABANDONED APPLICATION
PURSUANT TO 37 CFR § 1.137(b)**

Sir:

The above-identified application became abandoned due to Applicant's unintentional failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. Petitioner hereby requests revival of the application as an unintentionally abandoned application pursuant to 37 CFR § 1.137(b).

Pursuant to §1.137(b)(1), Petitioner is filing concurrently herewith a response to the outstanding Office Action to advance the prosecution of the application.

Since this utility application was filed on March 12, 2004, no terminal disclaimer is required.

Finally, Applicants hereby state that the entire delay in filing the required reply from the due date for the reply until the filing of this grantable petition under 37 CFR § 1.137(b) was unintentional and due to a docketing error.

The petition fee for other than a small entity is \$1,500.00 under 37 CFR § 1.17(m). Authorization is hereby provided to charge the amount of the fee under 37 C.F.R. §1.17(m), as well as any additional fees required, or to credit any overpayment to Deposit Account No. 16-1445.

Respectfully submitted,

Date: August 29, 2007
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4288

/ Martha G. Munchhof /
Martha G. Munchhof
Attorney for Applicant(s)
Reg. No. 47,811